Trastuzumab Emtansine Is the Standard Second-Line Treatment Following Horizontal Blockade in First Line of Advanced HER-2 Positive Breast Cancer: A Plant That Has Still to Grow

Integrative Cancer Science and Therapeutics
doi 10.15761/icst.1000302
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Open Access Text Pvt, Ltd.

Related search

Novel Approaches to Target HER2-positive Breast Cancer: Trastuzumab Emtansine

Cancer Management and Research
Oncology
2016English

Safety and Efficacy of Trastuzumab Emtansine in Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: A Meta-Analysis

Scientific Reports
Multidisciplinary
2016English

Clinical Experience of Dual Targeted Blockade (Pertuzumab + Trastuzumab + Docetaxel) in Neoadjuvant Therapy of Early HER-2-Positive Breast Cancer

Effective Pharmacotherapy
2019English

Mechanisms of Acquired Resistance to Trastuzumab Emtansine in Breast Cancer Cells

Molecular Cancer Therapeutics
Cancer ResearchOncology
2018English

Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab With Taxane for Human Epidermal Growth Factor Receptor 2–positive Advanced Breast Cancer: Final Results From MARIANNE

Cancer
Cancer ResearchOncology
2019English

An Open-Label Safety Study of Lapatinib Plus Trastuzumab Plus Paclitaxel in First-Line HER2-Positive Metastatic Breast Cancer

Oncologist
Cancer ResearchMedicineOncology
2013English

Pcn75 - Budget Impact Model of Subcutaneous Trastuzumab Compared With Intravenous Trastuzumab on the Treatment of Her-2 Positive Breast Cancer in the Brazilian Private Healthcare System

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Relationship Between Tumor Biomarkers and Efficacy in MARIANNE, a Phase III Study of Trastuzumab Emtansine ± Pertuzumab Versus Trastuzumab Plus Taxane in HER2-positive Advanced Breast Cancer

BMC Cancer
Cancer ResearchOncologyGenetics
2019English

Second-Line Treatment of Advanced Gastric Cancer: Where Do We Stand?

Journal of the National Comprehensive Cancer Network : JNCCN
MedicineOncology
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy